Fol­low­ing AS­CO show­ing, Bert Vo­gel­stein’s lat­est start­up launch­es in­to re­cur­rent can­cer de­tec­tion

Can­cer re­search lu­mi­nary Bert Vo­gel­stein is adding to his line of can­cer di­ag­nos­tic com­pa­nies, fol­low­ing Ex­act Sci­ences, In­os­tics, PGDx and Thrive (which was bought by Ex­act).

Haystack On­col­o­gy is launch­ing out of Catalio Cap­i­tal Man­age­ment, where Vo­gel­stein serves as a ven­ture part­ner as well. It’s start­ing out with a $56 mil­lion Se­ries A, adding to its $10 mil­lion in seed fund­ing, which was led by Catalio but al­so fea­tured re­search tool man­u­fac­tur­er Bruk­er, the ven­ture arm of Ex­act, and Alexan­dria Ven­ture In­vest­ments.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER